Astellas Pharma

Astellas Pharma Net Margin

The Net Profit Margin of Astellas Pharma (4503.T) as of Oct 18, 2026 is 13.63 %. In the previous year, Net Profit Margin was 2.65 % — a change of 413.55% (higher).

Net Margin

13.63 %

YoY

413.55%

Last updated:

Net Profit Margin of Astellas Pharma is 2026 13.63 % . Net Profit Margin of Astellas Pharma was 2025 2.65 % . It decreases by 413.55% higher compared to the previous year.

For Astellas Pharma, the net margin of 13.6% is up versus 9.6% a few years ago.

The Astellas Pharma Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
17.01 JPY
Jan 1, 2020
15.02 JPY
Jan 1, 2021
9.65 JPY
Jan 1, 2022
9.57 JPY
Jan 1, 2023
6.50 JPY
Jan 1, 2024
1.06 JPY
Jan 1, 2025
2.65 JPY
Jan 1, 2026
13.63 JPY
The Astellas Pharma Net Margin history
YEARNet MarginYoY
13.63 %+413.55%
2.65 %+149.67%
1.06 %-83.65%
6.50 %-32.10%
9.57 %-0.80%
9.65 %-35.76%
15.02 %-11.71%
17.01 %+34.35%
12.66 %-24.04%
16.67 %+18.17%
14.11 %+29.54%
10.89 %+36.63%
7.97 %+9,576.14%
0.08 %+2.09%
0.08 %+13.80%
0.07 %-43.45%
0.13 %-29.17%
0.18 %-2.95%
0.18 %+27.93%
0.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Astellas Pharma Stock analysis

What does Astellas Pharma do? Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Astellas Pharma stock

Net Profit Margin of Astellas Pharma is 13.63 % in 2026.

Net Profit Margin of Astellas Pharma changed from 2.65 % to 13.63 %, representing a 413.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Astellas Pharma since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Astellas Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Astellas Pharma

All Key Metrics — Astellas Pharma